Equally significant is the development of a novel anti‐canine CD20 antibody that offers targeted treatment potential for B‐cell lymphoma, echoing paradigm shifts observed in human lymphoma ...

For example, results from the phase 3 GOYA study of patients with aggressive B-cell lymphoma showed that an end-of-therapy PET scan showed a 74% reduced risk of death (HR, 0.26; 95% CI, 0.19-0.38 ...

T cells and/or bispecific antibody (BsAb) has been established and become a promising treatment strategy for ...

Diffuse large B-cell lymphoma is the most common type of lymphoma. It makes up approximately 25% of all non-Hodgkin’s lymphomas, which are cancers that lack defining cells called Hodgkin cells ...

Session ID: 2025-08-05:f5cefe8dc6db7b8819233254 Player Element ID: vjs_video_3 ...

Study Overview: BeiGene, Ltd. is conducting a Phase 2 study titled A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma ...

More information: David Stahl et al, CSF1R + myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma, Cancer Cell (2025). DOI: 10.1016/j.ccell.2025.05.013 ...

Targeting CD30 in Diffuse Large B-Cell Lymphoma: Where Does It Fit in? The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

Lymphoma highlights from ASCO 2025 include data on CAR-T cell therapy, zilovertamab vedotin in relapsed or refractory (R/R) LBCL, and optimal dosing of AFM13 plus AlloNK in R/R Hodgkin lymphoma.

The real-world effectiveness of Monjuvi (tafasitamab-cxix) in U.S. patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) was confirmed, along with factors associated with survival ...